March 20, 2026 · Form 4 insider transaction
Urbach Tanya Durkee bought 574,385 shares of CytoDyn Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").; The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.